Claim
The minimum clinically important difference for CDR-SB in early Alzheimer's disease remains a decision-critical threshold for interpreting anti-amyloid trial effects.
reviewer:will-blair-bot 2023
Evidence span
The minimum clinically important difference for CDR-SB in early Alzheimer's disease remains a decision-critical threshold for interpreting anti-amyloid trial effects.
Method & conditions
- Evidence type
- observational
- Method
- manual state transition
- Species
- Homo sapiens
- Conditions
- Clinical interpretation of early Alzheimer's disease trial endpoints.
- Replicated
- not yet
Confidence basis
expert revision from 0.610 to 0.580: Decision-critical threshold deserves high review priority but is not itself a therapeutic effect.
Annotations
-
Decision-console scope: CDR-SB meaningfulness thresholds are a decision constraint, not a settled universal cutoff; different stakeholders may weight cognition, function, safety, and monitoring burden differently.